Dr. Reddy’s Laboratories Ltd., announced the launch of Ketorolac Tromethamine Tablets USP, 10mg, a generic therapeutic equivalent of the reference drug Toradol Tablets, 10mg in the US market in partnership with Senores Pharmaceuticals, Inc.
The drug is approved by the United States Food and Drug Administration (USFDA).
The company stated in its press release, “Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug intended for the treatment of short-term (up to 5 days in adults) pain management moderately severe acute pain that requires opioid-level analgesia. and only as maintenance therapy after intravenous or intramuscular administration of ketorolac tromethamine, if necessary. »
“We are excited about the launch of this drug and excited about our partnership with Senores to create affordable access to this product and further expand our portfolio presence in the U.S. market,” said Marc Kikuchi, CEO, North America Generics, Dr. Reddy Laboratories.
“We are delighted to partner with Dr. Reddy’s Laboratories to launch ketorolac tromethamine tablets in the US market,” commented Dhananjay Barot, Director of Senores Pharmaceuticals, Inc.
Dr Reddys Laboratories is currently trading at Rs4,332, down Rs19.1 or 0.44% from its previous close of Rs4,351.10 on BSE. The certificate touched the intraday high and low of Rs4,396.35 and Rs4,324.80 respectively.
